Simon Cooper is the Managing Director of Adamson Jones, and an experienced patent and trade mark attorney. Simon holds a 1st class Masters of Physics degree from the University of Manchester.
Simon is the Director in charge of our Medical Devices Patent team, Electronics Patent team and our Trade Marks team. He advises a wide range of different companies in respect of IP, with a particular focus on patents and registered designs in the fields of mechanical and electrical engineering, medical devices and electronics, as well as associated trade mark protection. Simon is also experienced in contentious matters, including opposition before the EPO.
Simon is a Fellow of the Chartered Institute of Patent Attorneys (CIPA). Simon has joined the Education & Professional Standards Committee at CIPA, as chair of the External Affairs Working Group and a member of the Educational Activities Working Group.
Simon is a member of the European Patents Institute (EPI), the International Association for the Protection of Intellectual Property (AIPPI), the International Trademark Association (INTA), and the American Intellectual Property Law Association (AIPLA).
Simon is recommended in The Legal 500 UK 2017 rankings:
'Adamson Jones IP Ltd is traditionally strong in the life sciences space, but is increasingly active in the fields of chemistry, mechanical engineering and advanced physics. The group was reshaped in 2017 when Steve Jones retired from partnership; he remains as a consultant, and the team is now led by Simon Cooper. Highlights included assisting a university spin-out with its patent filing, and advising Intersurgical on a freedom to operate opinion in respect of a number of new products including an innovation which is being developed in collaboration with a US doctor. Nicholas Ferrar is also recommended.' Legal 500 UK 2017
Simon Cooper was recommended in the 2015 and 2016 Legal 500 UK rankings and was mentioned for having'outstanding knowledge and experience of the complex medical field.'
Director of IP, UK company
Katherine Wright, pharmaceutical patent attorney, comments on the risks of filing a patent application too early as recently highlighted in Regeneron v Kymab & Novo Nordisk.
All the latest news and events straight to your inbox. Fill in your details below.